SCLXW Scilex Holding Co

BEARISH Impact: 6/10 S-3
Horizon weeks Filed Jun 2, 2026 Processed 10d 12h ago SEC 0001193125-26-253831
Shelf registration — potential dilution
Latest settled — T+1d
SCLXW ▲ 0.00% at T+1d
SHORT call ✗ call lost 0.00% · α vs SPY +0.40% · entry $0.1360 → $0.1360
Next anchor: T+5d due 4d ago
Currently $0.1360 · -0.00% from $0.1360 entry (call sign-flipped)
Entry anchored
Jun 2, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.40%
$0.1360
settled 10d ago
T+5d
call — · α —
due 4d ago
T+20d
call — · α —
in 18d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Scilex Holding Company filed an S-3 shelf registration to register up to 2,083,067 primary shares issuable upon exercise of outstanding warrants and conversion of convertible notes, and up to 6,581,004 resale shares and 490,617 warrants held by selling securityholders. The filing is largely administrative — it consolidates prior registration statements and adds 100,000 new shares underlying a February 2026 warrant. The company's stock closed at $7.99 on June 1, 2026, far below virtually all warrant exercise prices (ranging from $22.72 to $402.50), making cash exercise highly unlikely. The company acknowledges it expects little to no cash proceeds. The 10-Q cross-filing context shows a complex capital structure with heavy dilution overhang and a going concern audit opinion.

Actionable Insight

This S-3 is a routine shelf consolidation with no new capital raise. The massive dilution overhang (warrants for ~8.6M shares vs 8.5M outstanding) and deeply out-of-the-money exercise prices mean the stock faces persistent overhang with no realistic path to cash exercise. Monitor for any reverse stock split or exercise price resets that could trigger dilution. The Deposit Warrant at $1.20 (15% of current price) held by insiders is the only warrant that could be exercised economically.

Key Facts

  • S-3 registers up to 2,083,067 primary shares issuable upon exercise of warrants and conversion of notes, plus 6,581,004 resale shares and 490,617 warrants held by selling securityholders
  • Only 100,000 new shares are being registered (February 2026 Warrant); the rest are carried forward from prior registration statements
  • Common stock closed at $7.99 on June 1, 2026 — below all warrant exercise prices ($22.72 to $402.50) and the Tranche B Note conversion price ($36.40)
  • Company states holders are 'unlikely to cash exercise their warrants or convert the outstanding note, resulting in little or no cash proceeds'
  • 8,491,267 shares outstanding as of April 30, 2026; fully diluted share count including all warrants/options exceeds ~17 million
  • Auditor's report contains a going concern explanatory paragraph (per incorporated 10-K)
  • Deposit Warrant with $1.20 exercise price for 3,250,000 shares was transferred to CEO Henry Ji for $500,000 and then partially to CFO Stephen Ma for $100,000 in April 2026

Financial Impact

Up to $144.9M potential proceeds from warrant exercise is theoretical — virtually all exercise prices are 2.8x to 50x above the $7.99 stock price, making cash exercise economically irrational. Realistic near-term cash proceeds are near zero.

dilutioncapital structurecash position

Risk Factors

  • Massive dilution overhang — warrants and convertible notes represent ~100% of current shares outstanding
  • Going concern audit opinion indicates potential liquidity distress
  • Insider-held Deposit Warrant at $1.20 exercise price could be exercised at any time, adding 3.25M shares (38% dilution) at a fraction of market price
  • All warrant exercise prices are deeply out-of-the-money, making cash exercise and associated proceeds highly unlikely
  • Cryptocurrency treasury strategy introduces additional volatility risk to balance sheet

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-253831
Document: d279959dexfilingfees.htm0001193125-26-253831
Document: d279959dex51.htm0001193125-26-253831
Document: d279959dex231.htm0001193125-26-253831
Document: 0001193125-26-253831-index-headers.html0001193125-26-253831
Document: 0001193125-26-253831-index.html0001193125-26-253831
Document: 0001193125-26-253831.txt0001193125-26-253831
5 reports for SCLXW
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SCLXW — sortable, filterable
Type Now
Jun 2, 2026
10d ago
S-3
BEARISH ★ 6/10
$0.1360 $0.1360· 0.00%▲ +0.40%$0.1360 (−0.00%)
May 26, 2026
18d ago
EFFECT
BEARISH ★ 6/10
$0.1360 $0.1360· 0.00%▲ +0.01%$0.1360 (−0.00%)
May 5, 2026
5w ago
8-K
BULLISH ★ 8/10
$0.1360 $0.1360· 0.00%▼ −1.38%$0.1360 (+0.00%)
Apr 28, 2026
6w ago
8-K
MIXED ★ 6/10
$0.1360 $0.1360· 0.00%▼ −1.02%$0.1360 (+0.00%)
Apr 16, 2026
8w ago
S-3
NEUTRAL ★ 4/10
$0.1360 $0.1360· 0.00%▲ +0.19%$0.1360 (+0.00%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (52h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access